Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities: 2017-2024

Historic Cash from Investing Activities for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $37.7 million.

  • Kiniksa Pharmaceuticals International's Cash from Investing Activities fell 888.58% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.9 million, marking a year-over-year decrease of 24.39%. This contributed to the annual value of $37.7 million for FY2024, which is 227.46% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Cash from Investing Activities stood at $37.7 million, which was up 227.46% from -$29.6 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cash from Investing Activities ranged from a high of $128.6 million in FY2021 and a low of -$29.6 million during FY2023.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Cash from Investing Activities had a median value of -$8.1 million in 2022 and averaged $12,333.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Cash from Investing Activities surged by 648.69% in 2021 and then crashed by 265.90% in 2023.
  • Kiniksa Pharmaceuticals International's Cash from Investing Activities (MRY) stood at -$23.4 million in 2020, then surged by 648.69% to $128.6 million in 2021, then crashed by 106.28% to -$8.1 million in 2022, then tumbled by 265.90% to -$29.6 million in 2023, then soared by 227.46% to $37.7 million in 2024.
  • Its last three reported values are $37.7 million in FY2024, -$29.6 million for FY2023, and -$8.1 million during FY2022.